ClinicalTrials.gg
CompletedNCT01324388Updated Oct 8, 2014Results posted

A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

A Phase 1 interventional study of LY2189265 and Metoprolol in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 3 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-10-08.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 — 3 open to participants now, 4 under way, 1 of them phase 3. dulaglutide · Diabetes Mellitus, Type 2.

Enrollment
41st of 54
51 · median 159
Started
2011
with 7 others
Phase 1
15 of 54
none open now
Registered
14th of 54
by date
Lead sponsor
43 of 54
Eli Lilly and Company

Among the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, this one is the 41st largest by enrollment, is one of 8 that started in 2011, is one of 15 in phase 1, and was the 14th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 54 studies testing dulaglutide in Diabetes Mellitus, Type 2 are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About dulaglutide

dulaglutide: first FDA approval 2014 (TRULICITY), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing dulaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of this study is twofold:

  1. To evaluate the effect of LY2189265 on how the body absorbs a blood pressure lowering drug (lisinopril) in participants with high blood pressure who are currently taking lisinopril.
  2. To evaluate the effect of LY2189265 on heart rate and blood pressure in healthy volunteers when taken with a Beta-blocker drug (metoprolol).

In Part 1, participants will receive four weekly injections of LY2189265 with continued use of normal lisinopril therapy.

Part 2 is a cross-over study design. Participants will receive a single injection of LY2189265 in one period, and seven daily doses of metoprolol and a single injection of LY2189265 in another period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male participants: agree to use a reliable method of during the study and for 3 months following the last dose of the product
  • Female participants: women not of due to menopause or surgical sterilization (at least 6 weeks post surgical bilateral oophorectomy, hysterectomy or tubal ligation) confirmed by medical history
  • Have a (BMI) of 18.5 to 40.0 kilograms/square meter (kg/m\^2), inclusive at the time of screening
  • Have clinical laboratory test results within normal reference range for the population or investigator site, or results with acceptable deviations that are judged to be not by the investigator
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • Are reliable and willing to make themselves available for the duration of the study and are willing to follow study restrictions
  • Have given written on an informed consent form (ICF) approved by Lilly and the corresponding ethics committee (EC) or ethical review board (ERB) governing the site

Part 1 only:

  • Have controlled mild to moderate hypertension (supine blood pressure [BP] less than or equal to 140/90 millimeter of mercury (mm Hg) at screening, or results with acceptable deviations that are judged not to be clinically significant by the investigator).
  • Males and females with stable medical problems (including Type 2 Diabetes Mellitus [T2DM]) that, in the investigator's opinion, will not significantly alter the disposition of the drug, will not place the participant at increased risk by participating in the study, and will not interfere with interpretation of the data may be included
  • Have been on oral antihypertensive medication (lisinopril daily [QD]) for at least 3 months prior to screening, have been on a stable dose for at least 1 month prior to screening, and are, in the investigator's opinion, able to safely adhere to a QD morning dosing regimen. Additional medication may be permitted as indicated

T2DM Participants (Part 1 only):

  • Have T2DM controlled with diet or exercise alone or stable on a single oral agent antihyperglycemic medication (metformin, sulfonylureas, repaglinide, nateglinide, acarbose [or other disaccharidase inhibitors] or thiazolidinediones) for at least 3 weeks (3 months for thiazolidinediones) prior to admission
  • Have a (HbA1c) value of 6.0% to 9.5% at screening or within 4 weeks prior to screening
  • Clinical laboratory test results within normal range or deemed clinically insignificant by the investigator. Abnormalities of serum glucose, serum lipids, urinary glucose, and urinary protein consistent with T2DM are acceptable

Part 2 only:

  • Are overtly healthy, as determined by medical history and physical examination

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled in, have completed or discontinued within the last 30 days from, a clinical trial involving an product; or are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Have known allergies to Glucagon-like peptide-1 (GLP-1)-related compounds, including LY2189265, or any components of the formulation
  • Are participants who have previously completed or withdrawn from this study, or have taken part in any other study investigating LY2189265 or GLP-1-related compounds within the last 3 months
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have a history or presence of gastrointestinal disorder (including pancreatitis [history of chronic pancreatitis or idiopathic acute pancreatitis] or gall bladder disease) or gastrointestinal disease that impacts gastric emptying (GE) (e.g. gastric bypass surgery, pyloric stenosis) or could be aggravated by GLP-1 analogs (for example; esophageal reflux). Participants having had cholecystectomy (removal of gall bladder) in the past with no further sequelae, may be included in the study at the discretion of the screening physician
  • Have a history or presence of thyroid disease, unless have been on a stable dose of thyroxine replacement therapy for at least 1 month
  • Show history or evidence of significant active neuropsychiatric disease
  • Have personal or family history of medullary thyroid cancer (MTC) or a genetic condition that predisposes to MTC
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Show evidence of (HIV) infection and/or positive human HIV antibodies
  • Show evidence of and/or positive hepatitis C antibody
  • Show evidence of and/or positive hepatitis B surface antigen
  • Intend to start new concomitant medication during the study, including over-the-counter and herbal medication, use drugs that directly reduce gastrointestinal motility or who regularly use systemic , or potent, inhaled, or intranasal steroids known to have a high rate of systemic absorption
  • Have donated more than 500 milliliters (mL) of blood within the month prior to screening
  • Have a nondominant arm circumference of greater than 42 centimeters (cm)
  • Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to stop alcohol consumption from 48 hours before each admission until discharge from the unit, and to limit alcohol intake to a maximum of 2 units/day on all other days from screening through 48 hours prior to the follow-up visit. (1 unit = 12 ounces [oz] or 360 mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits)
  • Are participants who, in the opinion of the investigator, are in any way unsuitable to participate in the study

Part 1 only:

  • Have any medical conditions, medical history or are taking any medication which are within the lisinopril product information leaflet

Part 2 only:

  • Intend to use over-the-counter medication (with the exception of paracetamol and/or antacids) within 7 days prior to dosing or prescription medication (with the exception of vitamin/mineral supplements and/or hormone replacement therapy and/or thyroid replacement therapy) within 14 days prior to dosing of the investigational product
  • Have any medical conditions, medical history or are taking any medication which are contraindicated within the metoprolol product information leaflet
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    LY2189265 + Lisinopril

    LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study. Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study.

    Biological: LY2189265 · Drug: Lisinopril

  • Placebo comparator
    Placebo + Lisinopril

    Placebo: 1.5 milligrams (mg), subcutaneous (SC), on Days 1, 8, 15, and 22 of Part 1 of the study. Lisinopril: Dose as prescribed by participant's established course of therapy, oral, daily dosing throughout Part 1 of the study.

    Drug: Lisinopril · Drug: Placebo

  • Experimental
    LY2189265 (Treatment 1)/Metoprolol + LY2189265 (Treatment 2)

    LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 1 of Treatment 1 and on Day 5 of Treatment 2 in Part 2 of the study. Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study. There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 1 of Treatment 1 to Day 1 of Treatment 2 in Part 2 of the study).

    Biological: LY2189265 · Drug: Metoprolol

  • Experimental
    Metoprolol + LY2189265 (Treatment 2)/LY2189265 (Treatment 1)

    LY2189265 (dulaglutide): 1.5 milligrams (mg), subcutaneous (SC), on Day 5 of Treatment 2 and on Day 1 of Treatment 1 in Part 2 of the study. Metoprolol: 100 mg, oral, on Days 1 through 7 of Treatment 2 in Part 2 of the study. There was a washout period of at least 21 days between the LY2189265 and metoprolol doses of each treatment period (Day 7 of Treatment 2 to Day 1 of Treatment 1 in Part 2 of the study).

    Biological: LY2189265 · Drug: Metoprolol

Interventions

  • BiologicalLY2189265

    Administered subcutaneously

    Also known as: dulaglutide

  • Administered orally

  • Administered orally

  • DrugPlacebo

    Administered subcutaneously

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril

    Time frame: Day -1, Day 3, Day 24 of Part 1

  2. Pharmacokinetics, Maximum Concentration (Cmax) of Lisinopril

    Time frame: Day -1, Day 3, Day 24 in Part 1

  3. Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol

    Time frame: Day -1, Day 4, Day 7 of Treatment 2 in Part 2

  4. Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol

    Time frame: Day -1, Day 4, Day 7 of Treatment 2 in Part 2

Secondary outcomes

  1. Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril

    Time frame: Day -1, Day 3, Day 24 of Part 1

  2. Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril

    Time frame: Day -1, Day 3, Day 24 of Part 1

  3. Pharmacokinetics, Area Under the Concentration Curve (AUC) of Metoprolol When Administered With LY2189265

    Time frame: Day 4 and Day 7 of Treatment 2 in Part 2

  4. Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265

    Time frame: Day 4 and Day 7 of Treatment 2 in Part 2

07

Results

Posted Oct 8, 2014

Participant flow

Part 1 of Study
Participant flow — Part 1 of Study
MilestonePart 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 First, Then LY2189265 + MetoprololPart 2: LY2189265 + Metoprolol First, Then LY2189265
Started23800
Received at least 1 dose23800
Completed19600
Not completed4200
Withdrew: Adverse event2000
Withdrew: Protocol violation1200
Withdrew: Physician decision1000
Part 2 of Study: First Intervention
Participant flow — Part 2 of Study: First Intervention
MilestonePart 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 First, Then LY2189265 + MetoprololPart 2: LY2189265 + Metoprolol First, Then LY2189265
Started001010
Completed00109
Not completed0001
Withdrew: Protocol violation0001
Part 2: Washout of at Least 21 Days
Participant flow — Part 2: Washout of at Least 21 Days
MilestonePart 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 First, Then LY2189265 + MetoprololPart 2: LY2189265 + Metoprolol First, Then LY2189265
Started00109
Completed00109
Not completed0000
Part 2 of Study: Second Intervention
Participant flow — Part 2 of Study: Second Intervention
MilestonePart 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 First, Then LY2189265 + MetoprololPart 2: LY2189265 + Metoprolol First, Then LY2189265
Started00109
Completed0099
Not completed0010
Withdrew: Withdrawal by subject0010

Outcome measures

PrimaryPharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril
Time frame:
Day -1, Day 3, Day 24 of Part 1
Reported as:
Geometric mean · (nanograms*hours/milliliter)/milligram
Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril
(nanograms*hours/milliliter)/milligramPart 1: LY2189265 + LisinoprilPart 1: Placebo + Lisinopril
Day -1 (Baseline)1580 ± 551740 ± 26
Day 3 (n=22, 8)1660 ± 561720 ± 28
Day 24 (n=18, 6)1540 ± 521390 ± 38
SecondaryMean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril
Time frame:
Day -1, Day 3, Day 24 of Part 1
Reported as:
Mean · beats per minute (bpm)
Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril
beats per minute (bpm)Part 1: LY2189265 + LisinoprilPart 1: Placebo + Lisinopril
Day -1 (Baseline)69.8 ± 8.968.9 ± 6.6
Day 3 (n=21, 6)78.3 ± 7.969.3 ± 9.0
Day 24 (n=18, 6)77.1 ± 9.071.6 ± 13.5
SecondaryMean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril
Time frame:
Day -1, Day 3, Day 24 of Part 1
Reported as:
Mean · millimeter of mercury (mm Hg)
Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Lisinopril
millimeter of mercury (mm Hg)Part 1: LY2189265 + LisinoprilPart 1: Placebo + Lisinopril
Systolic, Day -1 (Baseline)129.4 ± 14.1130.1 ± 14.9
Systolic, Day 3 (n=21, 6)125.3 ± 11.5127.1 ± 13.4
Systolic, Day 24 (n=18, 6)121.1 ± 10.3123.8 ± 16.2
Diastolic, Day -1 (Baseline)76.9 ± 8.674.1 ± 7.7
Diastolic, Day 3 (n=21, 6)77.1 ± 8.372.6 ± 5.1
Diastolic, Day 24 (n=18, 6)73.8 ± 9.471.2 ± 7.8
SecondaryPharmacokinetics, Area Under the Concentration Curve (AUC) of Metoprolol When Administered With LY2189265
Time frame:
Day 4 and Day 7 of Treatment 2 in Part 2
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*h/mL)
Pharmacokinetics, Area Under the Concentration Curve (AUC) of Metoprolol When Administered With LY2189265
nanograms*hour per milliliter (ng*h/mL)Part 2: LY2189265 + Metoprolol Crossover
Day 4617 ± 69
Day 7 (n=17)813 ± 63
SecondaryPharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265
Time frame:
Day 4 and Day 7 of Treatment 2 in Part 2
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics, Maximum Concentration (Cmax) of Metoprolol When Administered With LY2189265
nanograms per milliliter (ng/mL)Part 2: LY2189265 + Metoprolol Crossover
Day 435.7 ± 63
Day 7 (n=19)47.2 ± 66
PrimaryPharmacokinetics, Maximum Concentration (Cmax) of Lisinopril
Time frame:
Day -1, Day 3, Day 24 in Part 1
Reported as:
Geometric mean · (nanograms per milliliter) per milligram
Pharmacokinetics, Maximum Concentration (Cmax) of Lisinopril
(nanograms per milliliter) per milligramPart 1: LY2189265 + LisinoprilPart 1: Placebo + Lisinopril
Day -1 (Baseline)122 ± 56138 ± 22
Day 3 (n=22, 8)114 ± 55138 ± 25
Day 24 (n=18, 6)115 ± 49110 ± 39
PrimaryMean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol
Time frame:
Day -1, Day 4, Day 7 of Treatment 2 in Part 2
Reported as:
Mean · beats per minute (bpm)
Mean, 24-hour Heart Rate (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol
beats per minute (bpm)Part 2: LY2189265 + Metoprolol (Treatment 2)
Day -1 (Baseline)63.7 ± 9.6
Day 4 (n=18)55.8 ± 9.4
Day 769.4 ± 9.0
PrimaryMean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol
Time frame:
Day -1, Day 4, Day 7 of Treatment 2 in Part 2
Reported as:
Mean · millimeter of mercury (mm Hg)
Mean, 24-hour Blood Pressure (Collected by Ambulatory Blood Pressure Monitoring [ABPM]) in Response to Co-administration of LY2189265 and Metoprolol
millimeter of mercury (mm Hg)Part 2: LY2189265 + Metoprolol (Treatment 2)
Systolic, Day -1 (Baseline)123.0 ± 11.4
Systolic, Day 4 (n=18)115.4 ± 11.7
Systolic, Day 7116.2 ± 10.4
Diastolic, Day -1 (Baseline)72.8 ± 7.3
Diastolic, Day 4 (n=18)67.2 ± 7.5
Diastolic, Day 771.8 ± 6.4

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: LY2189265 + Lisinopril—0/23 (0%)13/23 (56.5%)
Part 1: Placebo + Lisinopril—0/8 (0%)1/8 (12.5%)
Part 2: LY2189265—0/19 (0%)7/19 (36.8%)
Part 2: Metoprolol—0/20 (0%)4/20 (20%)
Part 2: LY2189265 + Metoprolol—0/19 (0%)13/19 (68.4%)
Most frequent other events
Showing 10 of 26
Most frequent other events
EventPart 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265Part 2: MetoprololPart 2: LY2189265 + Metoprolol
Decreased appetiteMetabolism and nutrition disorders6/230/86/190/207/19
NauseaGastrointestinal disorders5/230/85/190/205/19
DyspepsiaGastrointestinal disorders5/230/81/190/200/19
Abdominal painGastrointestinal disorders4/230/81/191/200/19
HeadacheNervous system disorders3/230/80/190/201/19
FlatulenceGastrointestinal disorders0/231/80/190/201/19
Viral infectionInfections and infestations0/231/80/190/200/19
Procedural site reactionInjury, poisoning and procedural complications0/231/80/190/200/19
VomitingGastrointestinal disorders2/230/82/190/202/19
FatigueGeneral disorders0/230/80/190/202/19

Baseline characteristics

Participants who received at least one dose of study drug (LY2189265, placebo, or metoprolol).

Age, Continuous
Age, Continuous(years)Part 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 + Metoprolol CrossoverTotal
Mean57.2 ± 10.454.0 ± 13.044.6 ± 16.751.8 ± 14.6
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 + Metoprolol CrossoverTotal
Female111618
Male1271433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 + Metoprolol CrossoverTotal
Hispanic or Latino0123
Not Hispanic or Latino2371848
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 + Metoprolol CrossoverTotal
American Indian or Alaska Native0000
Asian40812
Native Hawaiian or Other Pacific Islander0000
Black or African American82111
White95923
More than one race2125
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Part 1: LY2189265 + LisinoprilPart 1: Placebo + LisinoprilPart 2: LY2189265 + Metoprolol CrossoverTotal
United States2382051
08

Study locations

3 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Honolulu, Hawaii 96813, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Evansville, Indiana 47710, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2011
First posted
Mar 29, 2011
Start
Mar 2011
Primary completionActual
Aug 2011
CompletionActual
Aug 2011
Results first posted
Oct 8, 2014
Last update
Oct 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01324388
Responsible party
Sponsor
First posted
Mar 29, 2011
Start date
Mar 2011
Primary completion
Aug 2011
Completion
Aug 2011
Results posted
Oct 8, 2014
Last update
Oct 8, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dulaglutide · Lisinopril

Start the discussion